Quality, Safety, and Practical Considerations of Using Biologic Therapies

摘要: Biologic medications including anti-TNF, anti-integrin, and anti-IL12/23 therapies induce remission clinical response among patients with inflammatory bowel diseases (IBD), Crohn’s disease (CD) ulcerative colitis (UC). Although generally safe, biologics may place the patient at a small increased risk for developing infections malignancy, latter likely more relevant when in combination thiopurines. The US Food Drug Administration (FDA) has added “boxed warnings” about of serious malignancy anti-TNF agents, although subsequent experience research have demonstrated that these are safe used appropriately. Successful use biologic requires an understanding contraindications, appropriate education, screening baseline lab testing, vaccination schedules prior to initiation or during therapy. In addition, drug selection, proper administration, safety monitoring treatment, after treatment discontinuation important understand medications. purpose this chapter is provide quality, safety, practical considerations using IBD.